JP2004501916A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004501916A5 JP2004501916A5 JP2002505776A JP2002505776A JP2004501916A5 JP 2004501916 A5 JP2004501916 A5 JP 2004501916A5 JP 2002505776 A JP2002505776 A JP 2002505776A JP 2002505776 A JP2002505776 A JP 2002505776A JP 2004501916 A5 JP2004501916 A5 JP 2004501916A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- alkoxyl
- alkyl
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- -1 1 - Chemical group 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000000034 method Methods 0.000 description 3
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical group C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 3
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ESP200001661 | 2000-06-27 | ||
| ES200001661 | 2000-06-27 | ||
| PCT/ES2001/000252 WO2002000652A1 (es) | 2000-06-27 | 2001-06-25 | Carbamatos derivados de arilalquilaminas |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004501916A JP2004501916A (ja) | 2004-01-22 |
| JP2004501916A5 true JP2004501916A5 (https=) | 2008-07-03 |
| JP5046465B2 JP5046465B2 (ja) | 2012-10-10 |
Family
ID=8494130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002505776A Expired - Fee Related JP5046465B2 (ja) | 2000-06-27 | 2001-06-25 | アリールアルキルアミンから誘導されるカルバメート |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US6916828B2 (https=) |
| EP (1) | EP1300407B2 (https=) |
| JP (1) | JP5046465B2 (https=) |
| KR (1) | KR100751981B1 (https=) |
| CN (1) | CN1227251C (https=) |
| AP (1) | AP1420A (https=) |
| AT (1) | ATE260277T1 (https=) |
| AU (2) | AU2001266100B9 (https=) |
| BG (1) | BG66102B1 (https=) |
| BR (1) | BR0112297A (https=) |
| CA (1) | CA2414514C (https=) |
| CR (1) | CR6889A (https=) |
| CZ (1) | CZ294251B6 (https=) |
| DE (2) | DE60102160T3 (https=) |
| DK (1) | DK1300407T4 (https=) |
| EA (1) | EA005520B1 (https=) |
| ES (1) | ES2213703T5 (https=) |
| HU (1) | HU229306B1 (https=) |
| IL (1) | IL153707A0 (https=) |
| MX (1) | MXPA03000141A (https=) |
| NO (1) | NO328499B1 (https=) |
| OA (1) | OA12300A (https=) |
| PL (1) | PL201530B1 (https=) |
| PT (1) | PT1300407E (https=) |
| SI (1) | SI1300407T2 (https=) |
| TR (1) | TR200400420T4 (https=) |
| UA (1) | UA72632C2 (https=) |
| WO (1) | WO2002000652A1 (https=) |
| ZA (1) | ZA200300644B (https=) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| KR100751981B1 (ko) * | 2000-06-27 | 2007-08-28 | 라보라토리오스 살바트, 에스.에이. | 아릴알킬아민으로부터 유도된 카바메이트 |
| NZ526580A (en) | 2000-12-22 | 2005-04-29 | Almirall Prodesfarma Ag | Quinuclidine carbamate derivatives and their use as M3 antagonists |
| DE60121813T2 (de) | 2000-12-28 | 2007-09-20 | Almirall Ag | Neue chinuclidinderivate und medizinische zusammensetzungen, die diese verbindungen enthalten |
| HUP0501017A3 (en) | 2001-12-14 | 2010-06-28 | Targacept | Methods and compositions for treatment of central nervous system disorders |
| JP4505227B2 (ja) * | 2001-12-20 | 2010-07-21 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | １−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用 |
| ES2203327B1 (es) * | 2002-06-21 | 2005-06-16 | Almirall Prodesfarma, S.A. | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
| ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
| AU2002345266B2 (en) | 2002-07-08 | 2009-07-02 | Ranbaxy Laboratories Limited | 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists |
| EP1618091A1 (en) | 2003-04-09 | 2006-01-25 | Ranbaxy Laboratories, Ltd. | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| JP2006522787A (ja) | 2003-04-11 | 2006-10-05 | ランバクシー ラボラトリーズ リミテッド | ムスカリン様受容体アンタゴニストとしてのアザビシクロ誘導体 |
| WO2004091597A2 (en) * | 2003-04-15 | 2004-10-28 | Pharmacia & Upjohn Company Llc | Method of treating irritable bowel syndrome (ibs) |
| AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| ES2246170B1 (es) * | 2004-07-29 | 2007-04-01 | Almirall Prodesfarma, S.A. | Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio. |
| GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0424284D0 (en) * | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US20090012116A1 (en) * | 2005-07-11 | 2009-01-08 | Naresh Kumar | Muscarinic Receptor Antagonists |
| US7732607B2 (en) * | 2005-08-22 | 2010-06-08 | Anatoly Mazurov | Heteroaryl-substituted diazatricycloalkanes and methods of use thereof |
| AU2006305619A1 (en) | 2005-10-19 | 2007-04-26 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of muscarinic receptor antagonists |
| WO2007045477A2 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Human antibodies against il-13 and therapeutic uses |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| PT2322525E (pt) | 2006-04-21 | 2013-12-26 | Novartis Ag | Derivados de purina para utilização como agonistas do recetor de adenosina a2a |
| EP1882691A1 (en) * | 2006-07-26 | 2008-01-30 | CHIESI FARMACEUTICI S.p.A. | Quinuclidine derivatives as M3 antagonists |
| WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
| RS51644B (sr) | 2007-01-10 | 2011-10-31 | Irm Llc. | Jedinjenja i preparati kao inhibitori kanal aktivirajuće proteaze |
| EP2119716A4 (en) | 2007-02-09 | 2011-06-01 | Astellas Pharma Inc | AZA BRIDGE CYCLE COMPOUND |
| CN101687851B (zh) | 2007-05-07 | 2013-02-27 | 诺瓦提斯公司 | 有机化合物 |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| WO2009046025A1 (en) * | 2007-10-01 | 2009-04-09 | Comentis, Inc. | Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease |
| EP2065385A1 (en) * | 2007-11-28 | 2009-06-03 | Laboratorios SALVAT, S.A. | Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester |
| CL2008003651A1 (es) | 2007-12-10 | 2009-06-19 | Novartis Ag | Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias. |
| AU2009203693B2 (en) | 2008-01-11 | 2012-06-07 | Novartis Ag | Pyrimidines as kinase inhibitors |
| KR20100113163A (ko) * | 2008-02-13 | 2010-10-20 | 타가셉트 인코포레이티드 | 알파 ７ 니코틴 작용제 및 항정신병제의 조합 |
| US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
| CA2727196A1 (en) | 2008-06-10 | 2009-12-17 | Novartis Ag | Organic compounds |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| PL2391366T3 (pl) | 2009-01-29 | 2013-04-30 | Novartis Ag | Podstawione benzimidazole do leczenia gwiaździaków |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| EA201200260A1 (ru) | 2009-08-12 | 2012-09-28 | Новартис Аг | Гетероциклические гидразоны и их применение для лечения рака и воспаления |
| NZ598220A (en) | 2009-08-17 | 2014-02-28 | Intellikine Llc | Heterocyclic compounds and uses thereof |
| CA2771432A1 (en) | 2009-08-20 | 2011-02-24 | Novartis Ag | Heterocyclic oxime compounds |
| US20110098311A1 (en) | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorported | Compositions for treatment of cystic fibrosis and other chronic diseases |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| WO2011137054A1 (en) | 2010-04-30 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel beta 3 adrenergic receptor agonists |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
| WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
| MA34969B1 (fr) | 2011-02-25 | 2014-03-01 | Irm Llc | Composes et compositions en tant qu inibiteurs de trk |
| US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
| CA2848809A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| ES2882807T3 (es) | 2011-09-16 | 2021-12-02 | Novartis Ag | Heterociclil carboxamidas N-sustituidas |
| WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
| WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| JP6130391B2 (ja) | 2011-11-23 | 2017-05-17 | インテリカイン， エルエルシー | Ｍｔｏｒ阻害剤を使用する強化された治療レジメン |
| US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
| AU2013243097A1 (en) | 2012-04-03 | 2014-10-09 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use |
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
| EP2968340A4 (en) | 2013-03-15 | 2016-08-10 | Intellikine Llc | COMBINING KINASE INHIBITORS AND USES THEREOF |
| JP6218940B2 (ja) * | 2013-07-13 | 2017-10-25 | ベイジン エフエスウェルカム テクノロジー ディベロップメント カンパニー リミテッド | キニン系化合物、その光学異性体及びその製造方法と医薬用途 |
| TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途 |
| KR102736869B1 (ko) | 2014-03-07 | 2024-12-02 | 바이오크리스트파마슈티컬즈,인코포레이티드 | 인간 혈장 칼리크레인 저해제 |
| CA2945212A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| BR112016024484A2 (pt) | 2014-04-24 | 2017-08-15 | Novartis Ag | derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase |
| US9862711B2 (en) | 2014-04-24 | 2018-01-09 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| JP2017524736A (ja) | 2014-07-11 | 2017-08-31 | アルファーマゲン，エルエルシー | アルファ７−ニコチン性アセチルコリン受容体活性を調節するためのキヌクリジン化合物 |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| CA2954862A1 (en) | 2014-07-31 | 2016-02-04 | Novartis Ag | Combination therapy |
| US9724340B2 (en) | 2015-07-31 | 2017-08-08 | Attenua, Inc. | Antitussive compositions and methods |
| CA3102279A1 (en) | 2018-06-01 | 2019-12-05 | Cornell University | Combination therapy for pi3k-associated disease or disorder |
| CN114040762A (zh) | 2019-02-04 | 2022-02-11 | 建新公司 | 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病 |
| AU2020290094B2 (en) | 2019-06-10 | 2024-01-18 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis |
| AU2020338971B2 (en) | 2019-08-28 | 2023-11-23 | Novartis Ag | Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
| JP2023512366A (ja) | 2020-02-03 | 2023-03-27 | ジェンザイム・コーポレーション | リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法 |
| AU2021311131B2 (en) | 2020-07-24 | 2026-02-19 | Genzyme Corporation | Pharmaceutical compositions comprising venglustat |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3287471A (en) | 1964-05-05 | 1966-11-22 | Searle & Co | Pyrrolidinyl nu-phenyl-nu-benzylcarbamates |
| JPH0495071A (ja) | 1990-08-10 | 1992-03-27 | Kyorin Pharmaceut Co Ltd | カルバミン酸誘導体 |
| WO1995006635A1 (en) * | 1993-09-02 | 1995-03-09 | Yamanouchi Pharmaceutical Co., Ltd. | Carbamate derivative and medicine containing the same |
| AU685225B2 (en) * | 1994-02-10 | 1998-01-15 | Yamanouchi Pharmaceutical Co., Ltd. | Novel carbamate derivative and medicinal composition containing the same |
| NO2005012I1 (no) * | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
| JPH08198751A (ja) * | 1995-01-19 | 1996-08-06 | Yamanouchi Pharmaceut Co Ltd | カルバメート誘導体 |
| KR100751981B1 (ko) * | 2000-06-27 | 2007-08-28 | 라보라토리오스 살바트, 에스.에이. | 아릴알킬아민으로부터 유도된 카바메이트 |
| NZ526580A (en) * | 2000-12-22 | 2005-04-29 | Almirall Prodesfarma Ag | Quinuclidine carbamate derivatives and their use as M3 antagonists |
| JP4505227B2 (ja) * | 2001-12-20 | 2010-07-21 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | １−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用 |
-
2001
- 2001-06-25 KR KR1020027017706A patent/KR100751981B1/ko not_active Expired - Fee Related
- 2001-06-25 DK DK01943553.6T patent/DK1300407T4/da active
- 2001-06-25 HU HU0301414A patent/HU229306B1/hu not_active IP Right Cessation
- 2001-06-25 AU AU2001266100A patent/AU2001266100B9/en not_active Ceased
- 2001-06-25 EP EP01943553A patent/EP1300407B2/en not_active Expired - Lifetime
- 2001-06-25 IL IL15370701A patent/IL153707A0/xx not_active IP Right Cessation
- 2001-06-25 US US10/312,227 patent/US6916828B2/en not_active Expired - Fee Related
- 2001-06-25 JP JP2002505776A patent/JP5046465B2/ja not_active Expired - Fee Related
- 2001-06-25 CZ CZ2003261A patent/CZ294251B6/cs not_active IP Right Cessation
- 2001-06-25 CN CNB018148042A patent/CN1227251C/zh not_active Expired - Fee Related
- 2001-06-25 OA OA1200200393A patent/OA12300A/en unknown
- 2001-06-25 BR BR0112297-5A patent/BR0112297A/pt active Search and Examination
- 2001-06-25 AT AT01943553T patent/ATE260277T1/de active
- 2001-06-25 AP APAP/P/2003/002722A patent/AP1420A/en active
- 2001-06-25 AU AU6610001A patent/AU6610001A/xx not_active Withdrawn
- 2001-06-25 WO PCT/ES2001/000252 patent/WO2002000652A1/es not_active Ceased
- 2001-06-25 MX MXPA03000141A patent/MXPA03000141A/es active IP Right Grant
- 2001-06-25 SI SI200130075T patent/SI1300407T2/sl unknown
- 2001-06-25 CA CA002414514A patent/CA2414514C/en not_active Expired - Fee Related
- 2001-06-25 ES ES01943553T patent/ES2213703T5/es not_active Expired - Lifetime
- 2001-06-25 DE DE60102160T patent/DE60102160T3/de not_active Expired - Lifetime
- 2001-06-25 TR TR2004/00420T patent/TR200400420T4/xx unknown
- 2001-06-25 EA EA200300072A patent/EA005520B1/ru not_active IP Right Cessation
- 2001-06-25 DE DE20122417U patent/DE20122417U1/de not_active Expired - Lifetime
- 2001-06-25 PL PL359333A patent/PL201530B1/pl unknown
- 2001-06-25 PT PT01943553T patent/PT1300407E/pt unknown
- 2001-06-25 UA UA2003010718A patent/UA72632C2/uk unknown
-
2002
- 2002-12-23 NO NO20026211A patent/NO328499B1/no not_active IP Right Cessation
-
2003
- 2003-01-17 BG BG107474A patent/BG66102B1/bg unknown
- 2003-01-20 CR CR6889A patent/CR6889A/es not_active Application Discontinuation
- 2003-01-23 ZA ZA200300644A patent/ZA200300644B/en unknown
-
2004
- 2004-06-23 US US10/875,592 patent/US7115629B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004501916A5 (https=) | ||
| CA2414514A1 (en) | Carbamates derived from arylalkylamines | |
| JP2020183410A5 (https=) | ||
| JP4295985B2 (ja) | 新規なキヌクリジン誘導体およびそれを含む医薬組成物 | |
| EP1461336B1 (en) | 1-alkyl-1-azoniabicyclo (2.2.2) octane carbamate derivatives and their use as muscarinic receptor antagonists | |
| JP2002531498A5 (https=) | ||
| JP2006501295A5 (https=) | ||
| JP2006514626A5 (https=) | ||
| AU2002238471A1 (en) | Quinuclidine derivatives and their use as M3 antagonists | |
| JP2004530641A5 (https=) | ||
| JP2002531578A5 (https=) | ||
| JP2005511698A5 (https=) | ||
| JP2005533826A5 (https=) | ||
| JP2005533860A5 (https=) | ||
| EA200970158A1 (ru) | Производные хинуклидина в качестве антагонистов м3 | |
| JP2002030084A5 (https=) | ||
| JP2004510813A5 (https=) | ||
| JP2008531558A5 (https=) | ||
| JP2005527521A5 (https=) | ||
| ZA200605931B (en) | New quaternized quinuclidine esters | |
| JP2005513004A5 (https=) | ||
| JP2006516643A5 (https=) | ||
| JP2002371059A5 (https=) | ||
| JP2007516292A5 (https=) | ||
| JP2008521775A5 (https=) |